Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

9.6

Margin Of Safety %

Put/Call OI Ratio

0.09

EPS Next Q Diff

-0.03

EPS Last/This Y

-1.21

EPS This/Next Y

1.77

Price

54.58

Target Price

73.18

Analyst Recom

1.18

Performance Q

4.24

Relative Volume

1.04

Beta

2.14

Ticker: RYTM




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2024-12-19RYTM55.520.180.129108
2024-12-20RYTM56.070.180.029095
2024-12-23RYTM56.010.071.456832
2024-12-24RYTM55.850.120.017439
2024-12-26RYTM56.920.120.007701
2024-12-27RYTM55.640.120.007716
2024-12-30RYTM56.30.110.007726
2024-12-31RYTM560.120.007666
2025-01-02RYTM60.10.120.117627
2025-01-03RYTM59.570.120.017447
2025-01-06RYTM58.910.120.007395
2025-01-07RYTM60.020.120.007587
2025-01-08RYTM57.780.120.157546
2025-01-09RYTM57.870.120.137546
2025-01-10RYTM56.160.120.027473
2025-01-13RYTM54.860.120.037801
2025-01-14RYTM53.960.110.008127
2025-01-15RYTM53.640.120.007723
2025-01-16RYTM54.610.100.009378
2025-01-17RYTM54.610.090.0110390
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2024-12-19RYTM55.46-14.7120.6-4.41
2024-12-20RYTM56.04-14.7123.4-4.41
2024-12-23RYTM56.04-14.7124.8-4.41
2024-12-24RYTM55.85-14.7125.0-4.41
2024-12-26RYTM56.54-14.7123.1-4.41
2024-12-27RYTM55.61-14.7126.7-4.41
2024-12-30RYTM56.30-14.7123.0-4.41
2024-12-31RYTM56.04-14.7125.3-4.41
2025-01-02RYTM60.00-14.7115.6-4.41
2025-01-03RYTM59.55-14.7125.7-4.41
2025-01-06RYTM58.91-14.7126.1-4.41
2025-01-07RYTM60.00-14.7122.4-4.41
2025-01-08RYTM57.87-14.7129.0-4.41
2025-01-09RYTM57.87-14.7124.6-4.41
2025-01-10RYTM56.16-14.7128.3-4.41
2025-01-13RYTM54.82-14.7127.6-4.41
2025-01-14RYTM53.91-14.7126.8-4.41
2025-01-15RYTM53.66-14.7125.3-4.41
2025-01-16RYTM54.59-14.7122.4-4.41
2025-01-17RYTM54.58-5.5124.8-4.41
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2024-12-19RYTM-3.49-3.3911.86
2024-12-20RYTM-3.49-3.3911.86
2024-12-23RYTM-3.45-3.3411.86
2024-12-24RYTM-3.45-3.3411.86
2024-12-26RYTM-3.50-3.3410.82
2024-12-27RYTM-3.49-3.3410.82
2024-12-30RYTM-3.55-3.3410.82
2024-12-31RYTM-3.55-3.3410.82
2025-01-02RYTM-3.51-3.3410.82
2025-01-03RYTM-3.49-3.3410.82
2025-01-06RYTM-3.51-3.3410.82
2025-01-07RYTM-3.51-3.3410.82
2025-01-08RYTM-3.49-3.3410.82
2025-01-09RYTM-4.08-3.3410.59
2025-01-10RYTM-4.08-3.3410.59
2025-01-13RYTM-4.08-3.349.60
2025-01-14RYTM-4.08-3.349.60
2025-01-15RYTM-4.08-3.349.60
2025-01-16RYTM-4.08-3.349.60
2025-01-17RYTM-4.01-3.349.60
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-0.73

Avg. EPS Est. Current Quarter

-0.8

Avg. EPS Est. Next Quarter

-0.76

Insider Transactions

-4.01

Institutional Transactions

-3.34

Beta

2.14

Average Sales Estimate Current Quarter

36

Average Sales Estimate Next Quarter

39

Fair Value

Quality Score

34

Growth Score

42

Sentiment Score

14

Actual DrawDown %

20.4

Max Drawdown 5-Year %

-92.1

Target Price

73.18

P/E

Forward P/E

PEG

P/S

29.79

P/B

298.77

P/Free Cash Flow

EPS

-4.34

Average EPS Est. Cur. Y​

-4.41

EPS Next Y. (Est.)

-2.64

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-232.41

Relative Volume

1.04

Return on Equity vs Sector %

-2328

Return on Equity vs Industry %

-2315.4

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

124.8
Rhythm Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 226
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
stock quote shares RYTM – Rhythm Pharmaceuticals Inc. Stock Price stock today
news today RYTM – Rhythm Pharmaceuticals Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RYTM – Rhythm Pharmaceuticals Inc. yahoo finance google finance
stock history RYTM – Rhythm Pharmaceuticals Inc. invest stock market
stock prices RYTM premarket after hours
ticker RYTM fair value insiders trading